Katie Couric Media

Forget the ‘Manosphere’—The ‘Meno-Sphere’ Is the Voting Bloc With Real Power

PUBLISHED 4/7/2026 by and

A recent report from centrist think tank Third Way predicts many of the “swingy, moderate, low-propensity young men” who supported Trump will sit out the midterms this year.

So who should progressive political strategists and hopefuls turn their attention to? The oft-forgotten, invisible aging woman, or, what we like to call the meno-sphere.

There are many good reasons to prioritize the electoral and mobilization potential of women over 50. Back in 1992, The New York Times published a piece called “Mighty Menopause,” which posited that the then-rise of Baby Boomer women in politics was a direct result of hormonal shifts and that the “biological changes wrought by menopause” ultimately bolster women’s “interest in power and increase their ability to use it.”

If ever there were a moment to prove that to be true, it’s now—as our daughters’ and granddaughters’ rights are rolled back, as communities are terrorized, as the power elite’s willful alignment with the rot becomes clearer by the day.

What’s Next for Menopause Legislation in Your State?

PUBLISHED 1/7/2026 by

An unprecedented 19 states have introduced three dozen bills to improve menopause care and treatment; eight of those bills are now law.

At the federal level, the U.S. Food and Drug Administration finally removed the “black box warning” on estrogen products, ushering in a new era for menopause care whereby women and their doctors can make decisions without the unnecessary fear the prior label engendered.

And so, we kick off the new year with a mighty impressive track record. Can we expect more of the same in 2026? My prediction is a resounding yes. This is only the beginning of a long overdue and much deeper series of demands. Here’s my forecast for what to expect in the weeks and months ahead.

This FDA Decision Could Transform Menopause Care

PUBLISHED 11/12/2025 by and

On Monday, Nov. 10, the U.S. Department of Health and Human Services announced that the Food and Drug Administration would eliminate the “boxed labeling” requirement for estrogen products.

The “black box warning,” as it’s commonly called, is part of the fallout from a press conference that occurred more than 20 years ago, announcing the findings of the Women’s Health Initiative (WHI). It’s also been the subject of a half-century-long push and pull with the federal government.

Make no mistake, this has been a longstanding demand—it’s neither new nor MAHA-driven. Doctors and scientists have made the case for its removal since the start to no avail, arguing the data from the WHI—the largest, most expensive, and only randomized placebo-controlled study of post-menopausal women—never supported putting it there in the first place.

The FDA’s reversal of the labeling requirement is a major win for evidence-based medicine. Now it’s up to us to responsibly inform women of their choices.